Introduction
Apoptosis is a fundamental mechanism of cell death that can be triggered by chemotherapeutic drugs. Understanding how the cell death program is engaged following an insult, and hence why it fails to be activated in certain settings, could offer a novel approach for overcoming the clinical problem of drug resistance. When a tumor does not respond to chemotherapeutic agents, this resistance is usually extended to more than one drug even structurally unrelated. This phenomenon is referred to as multidrug resistance (MDR) and it is the main cause of tumor treatment failure. Osteosarcoma is one of the most common primary tumors of bone, is highly malignant and typically affects children and adults. Osteosarcoma cells bear mutations of both p53 and pRb/p105 genes (Hansen, 1991) . In total, 30-40% of these tumors show a resistance to drugs after a few courses of chemotherapeutic treatment, which determines the failure of therapy. The mechanisms by which MDR is acquired in human osteosarcoma remain unclear. Overexpression of P-glycoprotein/p170, which works as an energy-dependent efflux pump for a diverse group of lipophilic compounds (Kane et al., 1990) , has been described as a possible factor for MDR in osteosarcoma tumors (Serra et al., 1993) . However, some other studies could not find any correlation between P-glycoprotein expression and clinical outcome in the patients with osteosarcoma (Gorlick et al., 1999) . Moreover, lack of expression of this drug resistancerelated protein does not appear to confer any advantage in terms of patient survival in osteosarcoma (Shnyder et al., 1998) . Transcription of MDR1 gene, which encodes for P-glycoprotein (Chen et al., 1986; Gottesman and Pastan, 1988) , is negatively regulated by wildtype p53 (wt-p53) and the presence of mutated p53 correlates with high expression of MDR1 (Thottassery et al., 1997) . p53 plays a pivotal role in modulating the cell response to various sources of damage and stress (Cinti et al., 2000; Vogelstein et al., 2000) by controlling the transcription of a large number of genes required for the apoptotic response (for a review, see Somasundaram and El-Deiry, 2000) . Given that p53 plays a crucial and multivariate role in controlling cell growth and survival, it is not surprising that it has been found mutated in the majority of cancers (for a review, see Sigal and Rotter, 2000) .
Each cell is able to integrate both extra-and intracellular survival and death signals, thereby controlling its own growth rate or, when harmful signals prevail, inducing its self-destruction. Mainly, this is achieved because of multiple interactions between the retinoblastoma family proteins (pRBs) pathway, whose main function is the control of G 1 to S progression, and the p53 pathway, which guards against genomic instability by inducing both arrest of the cell cycle and apoptosis. Moreover, it has recently been shown that E2F1, the main target of pRb/p105 growth suppressive function, plays a dual role, on the one hand by inducing S-promoting genes transcription and, on the other one, by directly influencing apoptosis execution. Mutations or functional inactivation because of post-translational modification of pRBs, p53 and/or of the other proteins involved in their functional pathways can also influence cellular sensitivity to chemotherapeutic drugs allowing cancer cells to evade apoptosis after drug-induced damage. Many links have been provided between both p53-dependent and -independent pathways and the pRb/p105 pathway. The most direct evidence of pRb/ p105 control on p53 proapoptotic activity is that it is able to prevent p53 degradation, mediated by MDM2, by forming a trimeric complex (Hsieh et al., 1999) . Interestingly, pRb/p105 acetylation is needed for pRb/ p105-MDM2 binding (Chan et al., 2001) . pRb/p105 deregulation determines unrestrained E2F1 expression, which may cause p53-dependent and -independent apoptosis (Hsieh et al., 1997; Johnson and SchneiderBroussard, 1998) . Namely, E2F1 has been shown to induce the accumulation of p53 (Hiebert et al., 1995; Kowalik et al., 1998) , the transcription of p73 (Stiewe and Putzer, 2000; Irwin et al., 2000) and the transcription of Apaf-1, a key element of apoptosome (Moroni et al., 2001) . Moreover, it has been reported that acetylation, dephosphorylation and consequent ubiquitin-mediated degradation of pRb/p105 retinoblastoma protein could be early events in programmed cell death, possibly related to cell commitment to apoptosis (for a review, see Dou and An, 1998) . As a consequence, failure to induce the interior cleavage of pRb/p105 can be associated with drug resistance to proapoptotic anticancer treatments . Up to now no similar data have been reported for the retinoblastomarelated gene pRb2/p130. Tumors concomitantly lacking pRb/p105 and p53, such as osteosarcoma cells, are, however, still able to undergo apoptosis, thus suggesting a possible role in this process of another pRB family protein to regulate the p53-dependent and -independent apoptosis. Few data are available on the role of the two retinoblastoma-related family members, pRb2/p130 and p107, in the apoptotic response even if a possible role of pRb2/p130 in regulating the expression of the antiapoptotic bcl-2 and of the proapoptotic p73 proteins has recently been indicated (Pucci et al., 2002) . Moreover, an inverse correlation between pRb2/p130 expression level and apoptotic index in retinoblastoma tumor has been reported, suggesting a possible involvement of pRb2/p130 in the apoptotic response (Bellan et al., 2002) .
Many genes, involved in both DNA replication and cell cycle control, have been shown to contain E2F sites in their promoter region (for a review, see Lavia and Jansen-Durr, 1999; Ren et al., 2002) , and it has been shown that E2F-binding sites mediate both transcriptional activation and repression (Dyson, 1998) . pRb2/ p130 controls the transcription of E2F responsive genes by forming a repressive complex on the promoters. pRb2/p130, in association with E2F4, is the most abundant E2F complex found in resting or in G0 quiescent cells, and this complex is thought to help in maintaining a state of transcriptional silence (Zini et al., 2001) . The presence of pRb2/p130-E2F4 DNA-binding complexes correlates with E2F1 gene repression and overexpression of pRb2/p130 inhibits transcription from the E2F1 promoter (Johnson, 1995) . In this manner, pRb2/p130 also regulates the expression of pRb/p105 and p107 genes because each contains E2F sites in their promoters. The pRB-E2F repressive complexes function in association with histone deacetylase (HDAC), essentially repressing the transcription of E2F-dependent genes probably through deacetylation of histone tails that protrude from nucleosome (Ferreira et al., 1998; Cress and Seto, 2000) . The shift from gene silencing to gene activation depends on the balance between nucleosome deacetylation and acetylation, possibly regulated by the replacement of HDAC with histone acetyltransferase (HAT) in pRB-E2F complexes directly recruited to E2F-regulated promoters (Rayman et al., 2002; Macaluso et al., 2003) . Interestingly, it has been shown that p73 gene expression is positively regulated by E2F1 transcription factor, which binds E2F sites on p73 promoter (Irwin et al., 2000; Seelan et al., 2002) . Moreover, it has recently been reported that, in p53-deficient tumor cells, endogenous p73 a and b proteins are upregulated in response to exogenous E2F1 overexpression and repressed by ectopically expressed pRb/p105 (Zaika et al., 2001; Seelan et al., 2002) . Despite significant advances in our understanding of the mechanisms underlying p53-independent apoptotic response and apoptosis evasion by MDR tumor cells, a complete characterization of the physiologically relevant factors involved in these processes has not yet been achieved. The aim of the present study is, on the one hand, to characterize the p53-independent pathway by which the osteosarcoma Hos cell line undergoes apoptosis and, on the other, to compare the results with those obtained in its HosDXR150 MDR variant.
Results

Characterization of HosDXR150 as an MDR clone
We selected a cell line resistant to chemotherapeutic agents (HosDXR150) by culturing a human osteosarcoma cell line (Hos) in the presence of increasing doses of doxorubicin hydrochloride (0.5-150 ng/ml). After application of 150 ng/ml doxorubicin, HosDXR150 growth rate slowed down initially (proliferation index 0.8 vs 1 in Hos parental cell line) and then speeded up after 96 h of treatment. In the same culturing conditions, the Hos cell line showed a marked decrease of the proliferation index (1 vs 0.2 after 96 h) (data not shown). To distinguish whether doxorubicin induced cell death in the Hos parental cell line by necrosis or apoptosis, we processed our samples for in situ Nick Translation assay. The apoptotic program is latent in virtually all cell types and, once triggered, unfolds following a precise sequence of events. Cells shrink to half their original volume, lose contacts with their neighbors, rearrange and condense their nuclear chromatin and, rarely but significantly, are caught in the act of implosion, emerging as condensed membrane-bounded bodies. As evidenced by confocal laser microscopy ( Figure 1 ) after treatment with 150 ng/ml doxorubicin, Hos cells showed changes characteristic of early ( Figure 1b ) and late apoptosis (Figure 1c) . To confirm the results obtained by confocal laser microscopy, we evaluated DNA fragmentation using agarose gel electrophoresis (DNA ladder). As shown in Figure 2 , after 24 h of doxorubicin treatment, Hos cells (third lane) already presented typical DNA oligonucleosome fragmentation, while the HosDXR150 clone (fifth lane) exhibited no DNA ladder pattern. The overall of these data showed that the HosDXR150 cell line evades the mechanism of apoptotic response induced by doxorubicin.
Resistance to one drug carries over resistance to unrelated anticancer drugs leading to MDR. Isolation of clones with MDR phenotype offers a model to investigate the mechanisms of MDR. As tumor cells often show crossresistance to a large variety of proapoptotic anticancer treatments, we evaluated the response of HosDXR150 to vinblastine sulfate, a drug that interferes with microtubule assembly thus inhibiting mitosis. In the presence of 50 ng/ml vinblastine, the Hos proliferation index lowered to 0.4 within 96 h, whereas doses up to 200 ng/ml were unable to block HosDXR150 growth (data not shown). We also determined the IC 50 value (the concentration resulting in 50% growth inhibition) in Hos and HosDXR150 incubated for 48 h in the presence of increasing doses of doxorubicin ( Figure 3a ) or vinblastine ( Figure 3b ). The Hos IC 50 value for doxorubicin treatment was about seven times lower than that evaluated in HosDXR150 (192 vs 1353 ng/ml), and HosDXR150 resistance to vinblastine treatment was even much more higher (about 90 times, 25 vs 2272 ng/ml). The crossresistance of the HosDXR150 clone to doxorubicin and vinblastine, two anticancer drugs that act by completely different mechanisms, strongly indicated that the selected clone has an MDR phenotype.
Recently, it has been shown that the MDR phenotype is characterized by overexpression of P-glycoprotein/ p170, an energy-dependent efflux pump whose function depends on Ca 2 þ ions. We investigated the expression of P-glycoprotein/p170 in Hos and HosDXR150 by Western blot analysis and characterized its distribution by confocal laser microscopy. Results are reported in Figure 4 . Western blot analysis revealed that P-glycoprotein/p170 was absent in parental cell line and overexpressed in chemoresistant HosDXR150 (Figure 4c ). Confocal laser microscopy confirmed that P-glycoprotein was not expressed in parental cell line ( Figure 4a ) whereas it accumulated in the MDR clone into the cytoplasmatic region ( Figure 4b ). Therefore, MDR in our model could be, at least in part, because of active extrusion of cytostatic agents by P-glycoprotein/ p170. To investigate to what extent P-glycoprotein/p170 overexpression determines MDR phenotype, we treated HosDXR150 with verapamil, a substance that antagonizes P-glycoprotein activity through competitive block of calcium channels. Actually, contemporary application of doxorubicin and 10 mm verapamil, a concentration known not to have a cytotoxic effect, to HosDXR150 halved the IC 50 value (734 vs 1353 ng/ml) but did not restore completely the apoptotic response ( Figure 5 ).
Comparison between Hos and HosDXR150: mutational status and gene expression profile
Overexpression of P-glycoprotein reflects MDR1 gene transcription that, in turn, is negatively regulated by wtp53 and the presence of mutated p53 correlates with high expression of MDR1 gene (Thottassery et al., 1997) . Therefore, we screened both Hos and HosDXR150 clones for mutations of p53 gene by PCR and sequencing of each p53 exon (Table 1) . We evidenced in both cell lines homozygous exon 5 point mutation at codon 156, Arg vs Pro, due to the substitution of G with C ( Figure 6 ). Loss of function of both p53 and pRb/p105 (Lin et al., 1994; Weinberg, 1995; Miller et al., 1996) in the Hos cell line determines deregulated cell proliferation and altered apoptotic response. Since pRB family members (pRb/p105, pRb2/p130 and p107) could exhibit overlapping specificities, we analysed the mutational status of Rb2/p130 gene. Sequencing analysis of Rb2/p130 retinoblastomarelated gene did not reveal any mutations in both cell lines (Table 2 ). This first series of experiments showed that Hos and HosDXR150 cells do not show differences in their mutational status. An alternative explanation to the reported differences between the two clones in susceptibility to Role of E2Fs-pRb2/p130 complexes in p73-dependent apoptosis D La Sala et al pharmacological treatments could derive from changes in the expression levels of genes codifying for proteins involved in both cell cycle arrest and apoptosis. Moreover, the presence of the same p53 homozygous point mutation, and the consequent functional inactivation of p53 in both parental and resistant cell lines, claims a further investigation aimed to identify the p53-independent pathway(s) by which the Hos cell line undergoes apoptosis while the MDR clone does not. Therefore, we screened the Hos cell line, at baseline condition and at various times after 150 ng/ml doxorubicin treatment, and the HosDXR150 clone for the expression of genes involved in apoptosis and/or cell cycle control (E2F1, p73, Apaf-1, bax, bcl-2, p21/Waf1, p27 Kip1 , pRb2/p130 and E2F4). As shown in Figure 7 , E2F1 expression level increased upon doxorubicin treatment and kept high until 12 h. E2F1 amount in HosDXR150 clone was comparable to what was observed in untreated Hos cell line. On the other hand, Apaf-1, whose transcription is controlled by E2F1 (Moroni et al., 2001 ) during apoptosis execution, was undetectable in both resistant and untreated sensitive osteosarcoma cell lines and its up-regulation was observed only in Hos cells after 4-6 h of doxorubicin treatment. Interestingly, E2F1 has recently been shown to directly activate also the transcription of p73, leading to activation of p53-responsive genes and apoptosis. p73 level already increased in the Hos cell line after 2 h of doxorubicin exposure and maintained a steady level for the next 6 h, decreasing below baseline level after 12 h. No difference in p73 expression level was detected between untreated parental and MDR cell lines. Bax is one of the p73-target genes and exerts its proapoptotic function by neutralizing bcl-2 antiapoptotic activity. The increased level of p73 in Hos cells, after 4-6 h doxorubicin treatment, induced bax overexpression and a corresponding bcl-2 downregulation. On the other hand, no differences in bax and bcl-2 expression levels were detectable in HosDXR150 with respect to the untreated Hos cell line. These results indicate that the Hos cell line undergoes apoptosis through an E2F1-and p73-dependent pathway while the HosDXR150 cells fail to activate it. Alterations of cell cycle regulators such as CDK inhibitors (i.e. p21/Waf1 and p27 Kip1 ), pRB family proteins (pRb/p105, pRb2/p130 and p107) and their transcription factors (E2F1-6) have been demonstrated to affect chemosensitivity by interfering with the mechanisms controlling cell cycle arrest. Analysis of the expression of these cell cycle regulators showed that p21/Waf1 did not change either in treated and untreated Hos or in HosDXR150 cell lines, while p27 Kip1 expression level increased after 4-6 h doxorubicin treatment only in Hos cells. Moreover, doxorubicin exposure induced an early evident decrease of pRb2/ p130 expression (2-4 h after treatment) followed by an increase restricted to its inactive hypo-and hyperphosphorylated forms (6 h) and exclusively to its inactive hyperphosphorylated form after 12-24 h in 
18712-18689
Figure 6 p53 gene sequence. Arrow indicates the homozygous point mutation on exon 5 at codon 156, Arg vs Pro, due to the substitution of G with C 
3540-3521
Role of E2Fs-pRb2/p130 complexes in p73-dependent apoptosis D La Sala et al the Hos cell line. On the contrary, both the active and inactive forms of pRb2/p130 were highly expressed in HosDXR150. It is known that the pRb2/p130 associates primarily with the E2F4 transcription factor to modulate the transcription of specific cell cycle genes. We found that the E2F4 expression level began to increase in the Hos cell line after 4 h reaching a peak after 6 h and subsequently decreasing to baseline level at 24 h. Even at its maximum, the E2F4 expression level in the Hos cell line never reached what was observed in HosDXR150. The differences found between the two clones in pRb2/p130 and E2F4 expression levels suggest that these two proteins might play a role in response to doxorubicin treatment.
In vivo p73 promoter occupancy in Hos and HosDXR150 cell lines
It has recently been shown that endogenous p73 a and b proteins are upregulated in osteosarcoma Saos cells, lacking both p53 and pRb/p105, in response to overexpression of E2F1 suggesting that E2F1 might regulate p73 expression (Stiewe and Pu¨tzer, 2000; Zaika et al., 2001 ). An important challenger in the study of transcriptional control during cell cycle progression and apoptosis in mammalian cells has been the identification of proteins that bind and regulate promoters under physiological conditions. Therefore, to study in vivo p73 promoter occupancy by E2Fs and pRb2/p130 in Hos and HosDXR150 cells, we performed chromatin immunoprecipitation (ChIP) assay in asynchronously growing Hos and HosDXR150 cells both treated with 150 ng/ml doxorubicin at various times. The immunoblottings were performed using antibodies against E2F1, E2F4, p300, HDAC1 and pRb2/p130. The same blots were stripped and reprobed sequentially. As a negative control for chromatin immunoprecipitation specificity, we used an irrelevant antibody. In Hos parental cells, we detected a multimolecular complex formed by E2F1-pRb2/p130-p300 bound to p73 promoter (Figure 8a ), while in HosDXR150 cells a multimolecular complex formed by E2F4-pRb2/p130-HDAC1 was bound to the same p73 promoter region ( Figure 8b ). We performed PCR by using primers flanking the p73 promoter region. We were able to amplify the p73 promoter fragment containing the region from À229 nt of the promoter to þ 81 nt of exon 1, where þ 1 represents the first nt of exon 1, from the chromatin immunoprecipitated by ChIP (Figure 9 ). Direct sequencing of PCR products confirmed that the immunoprecipitated DNA fragment corresponds to the p73 promoter (data not shown). This region confers the highest promoter activity residues since it has been identified to contain five putative E2F elements and a TATA box (Seelan et al., 2002) . The presence of E2F1-pRb2/p130-p300 complexes on the p73 promoter in the Hos cells which showed an increased p73 expression after genotoxic damage suggests that it could act as an activator of p73 transcription, thus triggering the apoptotic response. On the other hand, this proapoptotic pathway seems to be impaired in HosDXR150 by the presence of a repressive complex formed by E2F4-pRb2/p130-HDAC1 on the p73 promoter.
Discussion
In a first series of experiments, we characterized a putative MDR clone, HosDXR150, selected by culturing an osteosarcoma cell line, Hos, in the presence of increasing doxorubicin doses. We showed that, while the Hos parental cell line undergoes apoptosis upon drug treatment, HosDXR150 does not. This acquired resistance extends, even in higher degree, also to other pharmacological treatments, notwithstanding that they act through completely different mechanisms. In parti- Figure 7 Western blot analysis of genes involved in apoptosis and/ or cell cycle control: E2F1, Apaf1, p73, bax, bcl2, p21/Waf1, p27 Kip1 , pRb2/p130 and E2F4. In total 40 mg of Hos whole cell lysate at baseline condition and at various times after 150 ng/ml doxorubicin treatment, and of HosDXR150 cells were electrophoretically fractionated. Western blots were normalized by using a-actin antibody Role of E2Fs-pRb2/p130 complexes in p73-dependent apoptosis D La Sala et al cular, we showed that the HosDXR150 cells do not respond to treatment by vinblastine sulfate, a drug, which exerts its anticancer effect by interfering with mitotic spindle assembly while doxorubicin carries out antitumoral activity, similarly to others anthracyclines, by intercalating DNA, thus preventing its synthesis. Therefore, HosDXR150 cells have been shown to display a typical MDR phenotype. The lack of specificity for any pharmacological treatment in MDR can be explained by the observation that MDR tumors often overexpress P-glycoprotein/p170. P-glycoprotein acts as an energy-dependent efflux pump and extrudes a large variety of lipophilic compounds, thus preventing their effect whatever it is. This allows tumor cells to avoid the toxic effect of drugs and it is considered to confer chemoresistance to cancer cells. We showed that P-glycoprotein is overexpressed in HosDXR150 with respect to the sensitive Hos parental cell line and accumulates onto plasma membrane. However, active drug extrusion can only partially explain MDR in HosDXR150 as application of verapamil, which acts as an antagonistic agent of P-glycoprotein blocking Ca 2 þ channels, did not completely restore HosDXR150 sensitivity to doxorubicin. P-glycoprotein is the product of a gene, MDR1, which is usually kept repressed by wtp53, but can be activated by mutant p53 (Nguyen et al., 1994; ; for a review, see Sigal and Rotter, 2000) . We screened Hos and HosDXR150 for p53 mutations and evidenced in both cell lines the same homozygous point mutation at codon 156, inducing loss of p53 transactivation and DNA-binding abilities, thus confirming similar results already reported in both sensitive and MDR osteosarcoma cell lines (Park et al., 1994; Oda et al., 2000) . Anticancer treatments often switch on several pathways in tumor cells. Besides activation of transmembrane proteins extruding chemical substances from the cell, like P-glycoprotein, MDR may depend on deregulation of genes and proteins involved in the control of cell cycle progression and/or in apoptosis. This is particularly evident in the case of osteosarcoma whose prognosis and clinical outcome appear poorly correlated to increased expression level of both MDR1/P-glycoprotein and mutant p53 (Gorlick et al., 1999) . Therefore, since the sensitive osteosarcoma cell line showed an apoptotic response also in the presence of mutated p53, we investigated the possible p53-independent pathways underlying programmed cell death and compared the results with those obtained in its MDR variant in an attempt to identify alternative markers of MDR in osteosarcoma.
We compared the expression profile of genes involved in both apoptosis and cell cycle control in the Hos parental cell line at baseline conditions and at various times after doxorubicin treatment. Drug application induced upregulation of E2F1, p73, Apaf-1 and bax and downregulation of bcl-2. These results are in agreement with recent data suggesting a model of E2F1-induced apoptosis in which E2F1 overexpression directly regulates the transcription of p73 and Apaf-1 (Irwin et al., 2000; Stiewe and Putzer, 2000; Moroni et al., 2001) . High levels of p73 lead to the activation of p53-responsive target genes, like bax, while downregulation of bcl-2 moves the balance toward proapoptotic signaling (Stiewe and Putzer 2000; Costanzo et al., 2002) . E2F1 levels are higher than normal even in control Hos cells because of pRb/p105 functional inactivation, which has been shown in osteosarcoma primary tumors as well as in the Hos cell line and its nickel-resistant variant (Lin et al., 1994; Weinberg, 1995; Miller et al., 1996) . However, we report here a further increase upon doxorubicin treatment. E2F1 transcription is under pRb2/p130 and E2F4 control, which have been previously reported to be negative regulators of E2F1 expression (Johnson, 1995) . Therefore, we Figure 8 In vivo p73 promoter occupancy by pRb2/p130-E2F1-p300 and pRb2/p130-E2F4-HDAC1 in Hos (a) and HosDXR150 (b), respectively. ChIP analysis was performed by using antibody against E2F1 for Hos samples or E2F4 for HosDXR150 samples. The immunoblottings were performed using antibodies against pRb2/p130, E2F1, E2F4, HDAC1 and p300. The same blot was stripped and reprobed sequentially. The C lane corresponds to a negative control immunoprecipitation using an irrelevant antibody Figure 9 PCR of the chromatin immunoprecipitated by ChIP from Hos and HosDXR150 cells. The DNA was amplified using specific primers to amplify the p73 promoter fragment. The total chromatin (input), which represents 0.5% of the total amount of chromatin, was used as a positive control in each PCR reaction. The mock lane corresponds to a negative control of PCR reaction performed using DNA extracted by chromatin immunoprecipitated with an irrelevant antibody Role of E2Fs-pRb2/p130 complexes in p73-dependent apoptosis D La Sala et al screened untreated and treated Hos cell line also for pRb2/p130, which we showed to be wt in these cells, and E2F4. Initially, doxorubicin treatment induced a decrease in pRb2/p130 expression followed by an increase, which, as time progress, is restricted to its inactive phosphorylated forms. Phosphorylation determines the release of E2F4, whose expression level reaches a maximum after 6 h, and can also influence the protein stability by determining the probability of ubiquitinmediated degradation. Interestingly, it has been reported that, at an early stage of the apoptotic response, pRb/p105 first becomes dephosphorylated and immediately cleaved (for a review, see Dou and An, 1998) . Our observation of a decrease of pRb2/p130 expression within the first 2 h after doxorubicin treatment would suggest that this pRB family member also could undergo a similar early degradation related to apoptosis commitment. The major presence of pRb2/p130 inactive forms at later stages, concomitant to E2F4 overexpression, could result in removal of transcriptional repression by pRb2/p130-E2F4 complexes and underlie E2F1 overexpression. Analysis of the changes in the gene expression profile following doxorubicin treatment in the Hos-sensitive cell line strongly suggests that the apoptotic response is induced through an E2F1-and p73-dependent pathway. Moreover, we have shown that this same pathway is no more functional in the MDR HosDXR150. In fact, we did not observe any upregulation of E2F1 and p73 and, consequently, any change in bax/bcl-2 balance. pRb2/p130 is present with both its active and inactive forms and is therefore still able to act as a negative regulator of E2F1 transcription.
It has recently been reported that ectopic expression of pRb2/p130 is associated with downregulation of the antiapoptotic factor bcl-2 and upregulation of p73 (Pucci et al., 2002) , suggesting that it might regulate p73 expression. We studied the in vivo occupancy of p73 promoter by pRb2/p130 and our results suggest a direct role of this protein in regulating p73 expression. We found two distinct multimolecular complexes bound to a specific region of the p73 promoter and formed by E2F1-pRb2/p130-p300 in Hos and by E2F4-pRb2/ p130-HDAC1 in HosDXR150 cells. This result allows one depict a model for both apoptosis induction in Hos cell line and apoptosis evasion in HosDXR150. Genotoxic damage induced in Hos cells overexpression of E2F1 and p73 upregulation, which would be determined by an increase in its transcription due to binding of E2F1-pRb2/p130-p300 to its promoter region. On the other hand, in HosDXR150, p73 transcription would be maintained repressed by the presence of E2F4-pRb2/p130-HDAC1 complexes, thus preventing transactivation of p73 downstream proapoptotic genes. E2F-binding sites have been recently characterized in the human p73 promoter (Seelan et al., 2002) and in many other genes involved in both DNA replication and cell cycle control (for a review, see Lavia and JansenDurr, 1999) . Moreover, it has been shown that E2F-binding sites mediate both transcriptional activation and repression (Dyson, 1998) . The pRB-E2F repressive complexes function in association with HDAC, essentially repressing the transcription of E2F-dependent genes probably through deacetylation of histone tails that protrude from nucleosome (Ferreira et al., 1998; Cress and Seto 2000) . The shift from gene silencing to gene activation depends on the balance between nucleosome deacetylation and acetylation, possibly regulated by replacement of HDAC with HAT, like p300, in pRB-E2F complexes directly recruited to E2F-regulated promoters (Rayman et al., 2002; Macaluso et al., 2003) .
Our results provide an interesting link between E2Fs-pRb2/p130 complexes and specific chromatin-modifying factors in a physiological setting. In fact the recruitment of p300 or HDAC1 by pRb2/p130 on p73 promoter could be associated with the transcriptional level of this E2F-responsive gene. pRb2/p130 could modulate the structure and accessibility of chromatin by maintaining the balance between nucleosome acetylation and deacetylation. In sensitive osteosarcoma cells, recruitment of E2F1-Rb2/p130-p300 complexes on p73 promoter induces its expression, thereby triggering cell death. The presence of E2F4-pRb2/p130-HDAC1 repressive complexes on p73 promoter leads to failure of the apoptotic response in MDR osteosarcoma cells and could provide the mechanism by which this cell line evades the proapoptotic effect of chemotherapeutic drugs.
Materials and Methods
Chemotherapic drugs
Doxorubicin hydrochloride (DXR) was purchased from Pharmacia and Upjohn (Bentley, Australia), vinblastine sulfate (VLB) from Lilly SA (Fegersheim, France) and verapamil from Knoll Farmaceutici (Milan, Italy). The DXR, VLB and verapamil stock solutions were 2, 1 and 2.5 mg/ml, respectively.
Cell culture
Human osteosarcoma cell line (Hos) was cultured in Dulbecco's modified eagle medium (DMEM) supplemented with 10% heat-inactivated FCS at 371C in humidified 5% CO 2 atmosphere.
Doxorubucin-resistant osteosarcoma cells (HosDXR150) were obtained by continuous exposure of parental cells to increasing doses of DXR, 0.5-150 ng/ml. The drug concentration was raised anytime the growth rate of resistant subclone matched with that of the parental cell line. Approximately, 4-5 weeks were required to establish adequate growth at each new DXR concentration. DXR cells were continuously cultured in the presence of drug for at least 6 weeks before starting the experiments. To rule out the hypothesis that the selection could induce the appearance of hyperdiploid phenotype, the FACS analysis was performed. White blood cells were used as a diploid control. Cytofluorimetric analysis showed a normal diploid pattern in both cell lines.
Cell viability
Quantitative cell viability was measured by colorimetric assay using cell proliferation kit (MTT) (Roche Molecular Biochemicals, Germany). In all, 5000 cells/well Hos and HosDXR150 were grown in microtiter plates (96-well) in a final volume of 100 ml culture medium. The incubation period of cells culture was 24, 48, 72, 96 h in the presence or absence of the drug (150 ng/ml). After incubation period, 10 ml MTT labeling reagent was added to each well (final concentration 0.5 mg/ ml). MTT is cleaved by growing cells to form purple formazan crystals and allows quantification of cell viability by spectrophotometric analysis (ELISA) at 550 nm. Cell viability was expressed as the percentage of the absorbance of drug-treated cells relative to that of the control untreated cells.
IC 50 index
To determine the DXR-IC 50 value, the sensitive and resistant cells were incubated for 48 h in the presence of increasing doses of doxorubicin (10-5.000 ng/ml). To assess the selection of MDR phenotype, we determined the VLB-IC 50 value of cells in the presence of increasing doses of vinblastine (2-10 000 ng/ ml). Quantitative cell viability was measured by the MTT kit.
Reversal DXR resistance
The effect of verapamil on the in vitro sensitivity to doxorubicin was analysed in noncytotoxic conditions (10 mm) only on the subline HosDXR150 showing the high expression level of P-glycoprotein/p170. The decrease of DXR-IC 50 value in the presence of 10 mm verapamil was detected after 48 h and referred to as DXR-IC 50 after 48 h of incubation with only increasing doses of doxorubicin. To assess the cytotoxic effect of 10 mm verapamil on Hos drug-resistant clone, proliferation test was performed in the absence of doxorubicin.
Immunofluorescence and confocal laser scanning microscopy (CLSM)
Hos and HosDXR150 cells were grown on slides and fixed with 4% paraformaldehyde in 1 Â PBS. To detect the expression of P-glycoprotein/p170, the samples were incubated with primary monoclonal anti-P-glycoprotein (JSB1) antibody (Medac Diagnostika, Germany) and fluorescein isothiocyanate (FITC)-conjugated secondary antibody. DNA was counterstained with propidium iodide (PI) and slides were observed by a Sarastro 1000 microscope equipped with an argon ion laser. For the image acquisition, FITC and PI were excited simultaneously with the blue line (488 nm) of the argon ion laser. The emission signal was observed through a dichroic mirror (DM: 500 nm) followed by 595 nm DM and the combination of a band-pass filter (530715 nm) and cutoff filter (600 nm) to detect FITC and PI signals, respectively. For the three-dimensional reconstruction, optical sections were obtained at increments of 0.3 mm in the Z-axis, stored on the computer and the spatial projections were obtained by the Volume Analysis Software System (VANIS).
In situ nick translation
Cells were harvested by trypsin treatment, pelleted and fixed in methanol/acetic acid (3 : 1). Cell suspensions were spread onto slides and incubated with a solution containing: 2 U DNA polymerase I, 10 mm each of four deoxynucleotides, and digoxigenin-11-dUTP in 50 mm Tris-HCl pH 7.8, 5 mm MgCl 2 , 10 mm 2-mercaptoethanol. The samples were treated with 5% trichloroacetic acid (TCA) at 41C to remove unincorporated nucleotides and washed in Buffer I (1 m Tris base, 1 m NaCl, 20 mm MgCl 2 .6H 2 O, pH 7.5). The reaction was blocked by incubation for 20 min at 421C in Buffer I þ 2% BSA. The slides, incubated with FITC-conjugated antidigoxigenin antibody, were counterstained with 1 mg/ml PI and observed by a CLSM.
PCR analysis and sequencing
Genomic DNA was extracted from both Hos and HosDXR-150 cells. For p53 exons analysis, the PCR reaction mix (50 ml) contained genomic DNA at a final concentration of 4 ng/ml, 0.2 mm of each of the four deoxynucleotide triphosphates, 2 U of Taq I polymerase (Promega, USA) and p53 panel primers (Human p53 Amplimer Panels kit, Clontech, USA) at a final concentration of 0.4 mm each. The sequence of primers is shown in Table 1 . For p53 exon 4, new set of primers was used: P4ca:5 0 -GGGAAGCGAAAATTCATGGGAC-3 0 ; P4cb:5 0 -AGACTTCAATGCCTGGCCGTAT-3 0 . In all, 35 cycles of denaturation (951C, 1 min), annealing (661C, 1 min) and extension (721C, 1 min) linked to one cycle at 721C for 7 min were carried out. To amplify the entire Rb2/p130 cDNA, RT-PCR was performed using panel primers shown in Table 2 . Sequences of the purified PCR products were carried out by automated DNA sequencing using dideoxy-terminator reaction chemistry for sequence analysis on the Applied Biosystem model 373A DNA Sequencer.
Western blot assay
Whole-cell lysates were prepared by resuspending pelleted cells in lysis buffer (50 mm HEPES pH 7.5, 150 mm NaCl, 10% glycerol, 1% Triton X-100, 1 mm EGTA, 1.5 mm MgCl 2 , 100 mm NaF, 10 mm disodium pyrophosphate, 10 mg/ml aproptinin, 10 mg/ml leupeptin). Proteins (40 mg) were denatured by boiling in 2 Â sample buffer (100 mm Tris-HCl pH 6.8, 200 mm dithiothreitol, 2% SDS, 0.1% bromophenol blue, 10% glycerol) and size fractioned by electrophoresis in SDS/ polyacrylamide gel and transferred onto 0.2 mm nitrocellulose membrane (BioRad, USA). After saturation with 3% fat-free milk and 2% BSA solution, the membranes were incubated with the following monoclonal antibodies: anti-human-bax (2D2) (Kamiya Biomedical Company, USA) and anti-bcl-2a (100/D5) (Kamiya Biomedical Company, USA), anti-p53 (Ab6) (Calbiochem, Germany), anti-P-glycoprotein (JSB1) (Medac Diagnostika, Germany), anti-pRb2/p130 (10) (Transduction Laboratories, USA), and anti-p21/Waf-1 (4D10) (Medac Diagnostika, Germany), anti-E2F1 (KH95) (Santa Cruz Biotechnology, USA), anti-p27 Kip1 (57) (Transduction Laboratories, USA). For E2F4, p73 and Apaf-1 expression analyses polyclonal antibodies were used: anti-E2F4 antibody (C20), anti-p73 (H79), anti-Apaf-1 (N19) (Santa Cruz Biotechnology, USA). To normalize Western blot analysis, the antiactin antibody (Sigma Chemical, MO, USA) was used. After three washings with PBS-Tween-20, the membranes were incubated with secondary anti-mouse or anti-rabbit IgG, coupled with horseradish peroxidase (Amersham, Life Science, UK). Signal was detected using the ECL systemt (Amersham, Life Science, UK).
DNA ladder
Hos and HosDXR150 cells were harvested, pelleted and washed with 1X PBS. The pellet was resuspended in a lysis buffer (1% Nonidet P40, 10 U/ml Proteinase K in 1X PBS) and incubated for 15 min on ice. The samples were centrifuged for 15 min at 14 000 r.p.m., and the supernatant were separated and treated with 50 mg/ml of RNasei A for 30 min at 371C. Cell extracts were analysed by electrophoresis in 2% agarose gel.
In vivo promoter occupancy by pRb2/p130, E2Fs, HDAC1 and p300 using chromatin immunoprecipitation (ChIP) in the Hos and HosDXR150 cell lines
We performed ChIP using previously published methods (Orlando et al., 1997; Takahashi et al., 2000; Macaluso et al., 2003) . Exponentially growing Hos and HosDXR150 cells were fixed with formaldehyde and chromatin was solubilized by sonication. Immunoprecipitations were set up as indicated previously, using 2-4 mg of antibodies per immunoprecipitation. Antibodies against pRb2/p130, E2F1/4, HDAC1 and p300 were obtained from Santa Cruz Biotechnology and Upstate Biotechnology. An irrelevant antibody was used as a negative control in each immunoprecipitation. The immunocomplexes were recovered with protein A/G-Sepharose and immunoblotting was performed using the specified antibodies.
DNAs were purified from these immunoprecipitated chromatin/protein complexes, and PCR was performed using specific primers to amplify the p73 promoter (forward p73S: 5 0 -CGA CTT GGA CGC GGC CAG CT-3 0 and reverse p73R: 5 0 -CGA CGC TGC CGA CGT CCA TC-3 0 ). The total chromatin (input) was used as a positive control in each PCR reaction.
